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AbstrAct
Objectives
To conduct a comprehensive analysis of prospectively 
measured circulating high sensitivity C reactive 
protein (hsCRP) concentration and risk of lung cancer 
overall, by smoking status (never, former, and current 




20 population based cohort studies in Asia, Europe, 
Australia, and the United States.
ParticiPants
5299 patients with incident lung cancer, with 
individually incidence density matched controls.
exPOsure
Circulating hsCRP concentrations in prediagnostic 
serum or plasma samples.
Main OutcOMe Measure
Incident lung cancer diagnosis.
results
A positive association between circulating hsCRP 
concentration and the risk of lung cancer for current 
(odds ratio associated with a doubling in hsCRP 
concentration 1.09, 95% confidence interval 1.05 
to 1.13) and former smokers (1.09, 1.04 to 1.14) 
was observed, but not for never smokers (P<0.01 
for interaction). This association was strong and 
consistent across all histological subtypes, except for 
adenocarcinoma, which was not strongly associated 
with hsCRP concentration regardless of smoking 
status (odds ratio for adenocarcinoma overall 
0.97, 95% confidence interval 0.94 to 1.01). The 
association between circulating hsCRP concentration 
and the risk of lung cancer was strongest in the first 
two years of follow-up for former and current smokers. 
Including hsCRP concentration in a risk model, in 
addition to smoking based variables, did not improve 
risk discrimination overall, but slightly improved 
discrimination for cancers diagnosed in the first two 
years of follow-up.
cOnclusiOns
Former and current smokers with higher circulating 
hsCRP concentrations had a higher risk of lung cancer 
overall. Circulating hsCRP concentration was not 
associated with the risk of lung adenocarcinoma. 
Circulating hsCRP concentration could be a 
prediagnostic marker of lung cancer rather than a 
causal risk factor.
Introduction
Lung cancer is the leading cause of mortality related to 
cancer,1 accounting for 1.7 million deaths worldwide 
every year.2 Tobacco smoke exposure is known to cause 
most lung cancer cases,1 but a deeper understanding 
of intermediate factors that influence lung cancer 
pathogenesis is limited. In general, inflammation 
has been proposed to be an important risk factor for 
cancer, but the extent to which inflammation could 
drive the risk of lung cancer is unclear.3
C reactive protein (CRP) is an acute phase 
inflammatory protein that is synthesised in the liver in 
response to low grade inflammation.4 5 High sensitivity 
CRP (hsCRP) responds as a sensitive but non-specific 
biomarker for systemic inflammation. Two independent 
case-control studies nested in the Prostate, Lung, 
Colorectal, and Ovarian Cancer Screening Trial 
showed a positive association between circulating CRP 
concentrations and risk of lung cancer for current and 
WhAt Is AlreAdy knoWn on thIs topIc
Previous studies have shown that C reactive protein (CRP), a marker of systemic 
inflammation, is associated with the risk of lung cancer
The studies have not been sufficiently large to provide precise estimates of 
association by smoking status (never, former, or current smokers)
WhAt thIs study Adds
High sensitivity CRP (hsCRP) concentration is associated with the risk of lung 
cancer in former and current smokers, but not in never smokers 
The association is strongest in the first two years after blood draw 
hsCRP concentration is not associated with the risk of lung adenocarcinoma
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former smokers.6 More recently, an inverse association 
between CRP and the risk of lung cancer was reported 
for female never smokers, an important subgroup that 
the Prostate, Lung, Colorectal, and Ovarian Cancer 
Screening Trial was not adequately powered to assess.7
Both the low cost and increased availability of point-
of-care CRP tests in the primary care setting warrant 
further investigation into the potential use of CRP as 
a risk biomarker for lung cancer development.8-10 The 
primary objective of our study was to comprehensively 
investigate the relation between circulating hsCRP 
concentration and the risk of lung cancer for never, 
former, and current smokers. The secondary objective of 
our study was to conduct a risk discrimination analysis 
to evaluate whether circulating hsCRP concentration 
combined with self reported smoking information 
could better discriminate between current smokers at 
low and high risk of developing lung cancer, compared 
with self reported smoking information alone. This 
study used prediagnostic serum or plasma samples 
from 5299 individual incidence-density matched case-
control pairs in the Lung Cancer Cohort Consortium, 
which included 20 prospective cohorts from Asia, 
Europe, Australia, and the United States.
Methods
study population
All prospective cohorts with frozen baseline plasma 
or serum samples that were members of the US 
National Cancer Institute Cohort Consortium in 2009 
were invited to participate in the Lung Cancer Cohort 
Consortium. A total of 20 prospective cohorts from Asia, 
Europe, Australia, and the US were invited and agreed 
to participate in the Lung Cancer Cohort Consortium. 
At recruitment, research participants provided written 
informed consent to their respective cohorts, and the 
Lung Cancer Cohort Consortium project was approved 
by the institutional review boards of each participating 
institution. Participants in each cohort were followed 
up for incident cancer diagnoses and vital status, 
predominantly by linkage to population registers. 
Further details about Lung Cancer Cohort Consortium 
cohort recruitment and participant follow-up 
table 1 | Distribution of participant characteristics, overall and by region. values are numbers (percentages)
characteristic
Overall asia europe and australia us
control case control case control case control case
Total 5299 (100) 5299 (100) 1757 (100) 1757 (100) 1159 (100) 1159 (100) 2383 (100) 2383 (100)
Sex:
 Men 2873 (54) 2873 (54) 1218 (69) 1218 (69) 671 (58) 671 (58) 984 (41) 984 (41)
 Women 2426 (46) 2426 (46) 539 (31) 539 (31) 488 (42) 488 (42) 1399 (59) 1399 (59)
Smoking status:
 Never 1305 (25) 1305 (25) 592 (34) 592 (34) 147 (13) 147 (13 566 (24) 566 (24)
 Former 1498 (28) 1498 (28) 175 (10) 175 (10) 325 (28) 325 (28) 998 (42) 998 (42)
 Current 2496 (47) 2496 (47) 990 (56) 990 (56) 687 (59) 687 (59) 819 (34) 819 (34)
Age (years) at baseline:
 17-54 1539 (29) 1519 (29) 432 (25) 428 (24) 331 (29) 334 (29) 776 (33) 757 (32)
 55-59 997 (19) 991 (19) 377 (21) 365 (21) 251 (22) 251 (22) 369 (15) 375 (16)
 60-64 1238 (23) 1256 (24) 436 (25) 464 (26) 336 (29) 327 (28) 466 (20) 465 (20)
 65-86 1525 (29) 1533 (29) 512 (29) 500 (28) 241 (21) 247 (21) 772 (32) 786 (33)
Education:
 Less than high school 1670 (32) 1773 (33) 877 (50) 893 (51) 578 (50) 643 (55) 215 (9) 237 (10)
 Completed high school 774 (15) 753 (14) 228 (13) 242 (14) 175 (15) 155 (13) 371 (16) 56 (15)
 Vocational school 904 (17) 878 (17) 274 (16) 285 (16) 198 (17) 177 (15) 432 (18) 416 (17)
 Some college 707 (13) 670 (13) 192 (11) 168 (10) 127 (11) 105 (9) 388 (16) 397 (17)
 College graduate 492 (9) 518 (10) 113 (6) 102 (6) 63 (5) 61 (5) 316 (13) 355 (15)
 Graduate studies 707 (13) 640 (12) 64 (4) 59 (3) 8 (1) 10 (1) 635 (27) 571 (24)
 Missing 45 (1) 67 (1) 9 (1) 8 (0) 10 (1) 8 (1) 26 (1) 51 (2)
Body mass index (kg/m2):
 14.1-24.9 2769 (52) 2973 (56) 1291 (73) 1347 (7) 434 (37) 519 (45) 1044 (44) 1107 (46)
 25.0-29.9 1795 (34) 1658 (31) 420 (24) 364 (21) 524 (45) 457 (39) 851 (36) 837 (35)
 30.0-59.5 673 (13) 604 (11) 46 (3) 46 (3) 199 (17) 182 (16) 428 (18) 376 (16)
 Missing 62 (1) 64 (1) 0 (0) 0 (0) 2 (0) 1 (0) 60 (3) 63 (3)
hsCRP (µg/mL):
 0.00388-0.731 1325 (25) 1180 (22) 610 (35) 540 (31) 275 (24) 243 (21) 440 (18) 397 (17)
 0.732-1.76 1320 (25) 1242 (23) 468 (27) 455 (26) 312 (27) 280 (24) 540 (23) 507 (21)
 1.77-4.13 1326 (25) 1384 (26) 372 (21) 390 (22) 304 (26) 314 (27) 650 (27) 680 (29)
 4.14-87.9 1328 (25) 1493 (28) 307 (17) 372 (21) 268 (23) 322 (28) 753 (32) 799 (34)
table 2 | clinical characteristics of lung cancer cases, overall and by region. values are 
numbers (percentages)
characteristics Overall asia europe and australia us
Time (years) from blood draw to diagnosis: 
 0.0-1.9 583 (11) 257 (15) 82 (7) 244 (10)
 2.0-4.9 1325 (25) 463 (26) 134 (12) 728 (31)
 5.0-9.9 1631 (31) 613 (35) 362 (31) 656 (28)
 10.0-35.6 1577 (30) 424 (24) 581 (50) 572 (24)
Histology:
 Large cell 173 (3) 16 (1) 46 (4) 111 (5)
 Small cell 484 (9) 98 (6) 146 (13) 240 (10)
 Squamous cell 831 (16) 319 (18) 226 (19) 286 (12)
 Adenocarcinoma 2030 (38) 608 (35) 398 (34) 1024 (43)
 Other 595 (11) 124 (7) 178 (15) 293 (12)
 Unknown or missing 1186 (22) 592 (4) 165 (14) 429 (18)
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procedures have been published,11 and are available 
in the supplementary materials.
selection of cases and controls
We defined lung cancer cases as all invasive cancers 
with ICD-O-2 (international classification of diseases 
for oncology, 2nd edition) codes C34.0 to C34.9. Former 
and never smokers were intentionally oversampled 
to improve statistical power in analyses stratified by 
smoking. We randomly selected controls for each 
case from risk-sets of patients who were alive and free 
of cancer at the time of diagnosis of their index case 
(incidence density matching). Cases and controls were 
individually matched by cohort, sex (male or female), 
age (initially ±1 year, relaxed to ±3 years), ethnic group 
(US cohorts only), date of blood draw (initially ±1 
table 3 | Odds ratios for lung cancer by high sensitivity c reactive protein (hscrP) 
concentration in fourths, and for a doubling in hscrP concentration 
hscrP concentration no of controls no of cases Odds ratio (95% ci) P value
Categorical (μg/mL):     
 0.00388-0.731 1325 1180 1.00 (ref) <0.001
 0.732-1.76 1320 1242 1.05 (0.93 to 1.17)  
 1.77-4.13 1326 1384 1.17 (1.04 to 1.31)  
 4.14-87.9 1328 1493 1.26 (1.12 to 1.41)  
Continuous:     
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  Large cell
  Small cell
  Squamous cell
  Adenocarcinoma
  Other
  Unknown or missing
1.05 (1.03 to 1.08)
0.95 (0.91 to 1.00)
1.09 (1.04 to 1.14)
1.09 (1.05 to 1.13)
1.10 (1.06 to 1.13)
1.01 (0.97 to 1.04)
1.06 (1.02 to 1.11)
1.06 (1.01 to 1.12)
1.04 (1.01 to 1.08)
1.04 (1.00 to 1.08)
1.08 (1.02 to 1.14)
1.04 (1.00 to 1.09)
1.07 (1.02 to 1.11)
1.10 (1.06 to 1.14)
1.03 (0.98 to 1.09)
1.02 (0.96 to 1.07)
1.03 (0.97 to 1.10)
1.03 (0.95 to 1.10)
1.06 (0.99 to 1.13)
1.06 (1.03 to 1.10)
1.09 (1.04 to 1.14)
1.03 (0.96 to 1.11)
1.21 (1.13 to 1.29)
1.04 (0.99 to 1.09)
1.02 (0.98 to 1.06)
1.05 (1.01 to 1.10)
1.07 (0.93 to 1.23)
1.09 (1.01 to 1.18)
1.13 (1.07 to 1.19)
0.97 (0.94 to 1.01)
1.08 (1.01 to 1.16)
1.12 (1.06 to 1.17)















































Fig 1 | Odds ratios for doubling in high sensitivity c reactive protein (hscrP) concentration, overall and by participant 
characteristics. P values are from likelihood ratio tests of the interaction between hscrP and each covariate
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month, relaxed to ±3 months), and number of freeze-
thaw cycles of their blood sample (0 or 1). We further 
matched cases and controls by smoking status in five 
categories: never smokers, short and long term quitters 
among former smokers (<10 years, ≥10 years since 
quitting), and light and heavy smokers among current 
smokers (<15 cigarettes per day, ≥15 cigarettes per 
day). Our self reported smoking covariates (smoking 
status, smoking duration, and smoking intensity) 
include tobacco use from cigarettes, cigars, and 
pipes. By convention, we refer to smoking intensity 
as cigarettes per day, even though the cigarettes per 
day variable in the current analysis also includes 
information on cigars and pipes. After matching and 
biochemical analyses, we used a total of 5299 case-
control pairs in the current analysis, including 2496 
current smoker pairs, 1498 former smoker pairs, and 
1305 never smoker pairs.
biochemical analysis
Centralised biochemical analyses of serum or 
plasma hsCRP and serum or plasma cotinine were 
performed at the BEVITAL Laboratory in Bergen, 
Norway. Quantification of serum or plasma hsCRP 
was conducted by using Immuno-MALDI-MS.12 
For hsCRP, the lower limit of detection was 0.1 μg/
mL, the within-day coefficient of variation was 3% 
to 6%, and the between-day coefficient of variation 
was 3% to 7%. Quantification of serum or plasma 
cotinine was performed by liquid chromatography-
mass spectrometry (LC-MS/MS).13 For cotinine, the 
lower limit of detection was 1 nmol/L, the within-day 
coefficient of variation was 2% to 3%, and the between-
day coefficient of variation was 6%. The intraclass 
correlation coefficient of cotinine was 0.89-0.95.14
statistical analyses
We used conditional logistic regression to calculate 
odds ratios and 95% confidence intervals for incident 
lung cancer per fourths of hsCRP concentration. We 
also analysed hsCRP concentration as a continuous 
exposure variable by using the base 2 logarithm of 
hsCRP (ORlog2CRP). ORlog2CRP estimates can be interpreted 
as the relative risk associated with a doubling in hsCRP 
concentration. Estimates from conditional logistic 
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Fig 2 | Odds ratios for doubling in high sensitivity c reactive protein (hscrP) concentration for current smokers 
by participant characteristics. P values are from likelihood ratio tests of the interaction between hscrP and each 
covariate
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set and adjusted for fourths of circulating cotinine 
concentration. P values were from likelihood ratio tests 
of the hsCRP terms.
In addition to controlling for tobacco exposure 
by the smoking-matched study design, we further 
adjusted models for circulating cotinine concentration 
(in fourths). All risk analyses were conducted overall, 
and stratified by smoking status (never, former, and 
current, to have sufficient sample size in each group 
for the stratified estimates), and region (Asia, Europe 
and Australia (combined to ensure sufficient sample 
size), and the US). Further stratified risk analyses 
were conducted by sociodemographic and clinical 
variables, including the following: sex, age at baseline 
(years), body mass index (kg/m2), and time from 
blood draw to diagnosis (years). We also stratified by 
histological subtype (large cell, small cell, squamous 
cell, adenocarcinoma, other, and unknown or 
missing). Heterogeneity of these stratified estimates 
was evaluated using the likelihood ratio test of the 
interaction terms between hsCRP and each covariate.
To evaluate if circulating hsCRP concentration 
combined with self reported smoking information (CRP 
model) could improve discrimination between current 
smokers at high and low risk of lung cancer compared 
with self reported smoking information alone (base 
model), we calculated the area under the receiver 
operating characteristic curve (AUC) for each model. 
Self reported smoking models included smoking 
status; number of cigarettes, cigars, and pipes per day; 
and duration of smoking (number of years participant 
regularly smoked cigarettes, pipes, or cigars). Both 
cigars and pipes per day and smoking duration 
were modelled using restricted cubic splines with 3 
degrees of freedom. These models were fitted to data 
from current smokers. We further fitted these models 
restricting the analysis to cases diagnosed within the 
first two years of follow-up and their matched controls 
(time from blood draw to diagnosis of two years or 
less).
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Fig 3 | Odds ratios for doubling in high sensitivity c reactive protein (hscrP) concentration for former smokers 
by participant characteristics. P values are from likelihood ratio tests of the interaction between hscrP and each 
covariate
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Patient and public involvement
No patients were involved in setting the research 
question or the outcome measures, nor were they 
involved in developing plans for recruitment, design, 
or implementation of the study. No patients were asked 
to advise on interpretation or writing up of results.
results
Table 1 shows that our study sample included 5299 
incident lung cancer cases and 5299 individually 
matched controls. Overall, slightly more participants 
were male (54%). Participants from cohorts in Asia 
and Europe and Australia were also predominantly 
male (69% and 58%, respectively). Current smokers 
accounted for nearly half of the overall study sample 
(47%, 2496 case-control pairs), with former and 
never smokers contributing approximately one 
quarter each (former 28%, 1498 case-control pairs; 
never 25%, 1305 case-control pairs). Median age 
at cohort recruitment was 60 years (table 1). Cases 
and controls had similar characteristics, on average, 
except for body mass index, for which a smaller 
proportion of cases had body mass index greater than 
25 kg/m2. Circulating cotinine showed considerable 
variability among self reported current smokers, 
whereas most never and former smokers did not have 
detectable cotinine concentrations (supplementary 
materials, fig 1).
Table 2 shows that the median time between blood 
draw and lung cancer diagnosis for cases was 6.8 years. 
Table 2 shows that most lung cancer cases, overall 
and by region, were diagnosed with adenocarcinoma, 
followed by squamous cell, small cell, and large cell 
carcinomas. Overall, 38% of cancers in the sample 
were adenocarcinomas (43% of those cancers 
diagnosed in the US, compared with 35% for Asia and 
34% for Europe and Australia). 
Table 3 shows that higher hsCRP concentration 
was positively associated with the overall risk of lung 
cancer (odds ratio 1.05, 95% confidence interval 1.03 
to 1.08, P<0.001 for trend). Associations between 
hsCRP concentration and the risk of lung cancer were 
slightly stronger in models without adjustment for 
circulating cotinine (supplementary materials, table 1). 
Figure 1 shows that the association was most apparent 
for current (odds ratio 1.09, 95% confidence interval 
1.05 to 1.13) and former smokers (1.09, 1.04 to 
1.14). We did not observe a positive association for 
never smokers (0.95, 0.91 to 1.00; fig 1). Figure 1 
shows that the positive association between hsCRP 
concentration and the risk of lung cancer was stronger 
for patients who were diagnosed in the first two years 
of follow-up (odds ratio 1.21, 95% confidence interval 
1.13 to 1.29, P<0.01 for interaction). There was also 
some indication that the association was stronger for 
participants in the less than high school education 
group, though there was little statistical evidence 
for heterogeneity, and this is likely driven by the 
greater proportion of current smokers in this group 
(supplementary materials, table 2).
Further stratified risk analyses showed that the 
association between hsCRP concentration and the 
risk of lung cancer differed by histological subtype 
(P<0.01 for interaction for overall risk of lung cancer, 
fig 1; P=0.15 for interaction for current smokers, 
fig 2; and P<0.01 for former smokers, fig 3). For 
instance, although we observed a strong and consistent 
association between hsCRP concentration and the risk 
of squamous cell lung cancer among current (odds 
ratio 1.16, 95% confidence interval 1.08 to 1.24, 
fig 2) and former (1.15, 1.02 to 1.28, fig 3) smokers, 
no corresponding association was observed for 
adenocarcinoma among current (1.03, 0.96 to 1.10, 
fig 2) and former (0.98, 0.91 to 1.05, fig 3) smokers.
Figure 4A shows that for current smokers overall, 
combining hsCRP concentration and self reported 
smoking information into an integrated model (CRP 
model) did not improve discriminative performance 
when compared with the base model, which only 
included self reported smoking variables (AUCCRP model 
0.68, 95% confidence interval 0.66 to 0.69; 
A
Base model: AUC = 0.67 (0.66 to 0.69)













Base model: AUC = 0.76 (0.72 to 0.81)
















Fig 4 | current smokers a overall (n=2199 case-control 
pairs) and b with time from blood draw to diagnosis ≤2 
years (n=224 case-control pairs)
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AUCBase model 0.67, 95% confidence interval 0.66 to 
0.69). Figure 4B shows that for current smokers with a 
time from blood draw to diagnosis of two years or less, 
the CRP model did provide further risk discriminative 
information (AUCCRP model 0.80, 95% confidence interval 
0.76 to 0.84) compared with self reported smoking 
alone (AUCBase model 0.76, 95% confidence interval 0.72 
to 0.81).
discussion
We conducted a comprehensive analysis of the relation 
between circulating hsCRP concentration and the 
risk of lung cancer by using prediagnostic samples 
from 20 prospective cohorts in the Lung Cancer 
Cohort Consortium. Former and current smokers with 
higher hsCRP concentrations had an increased risk 
for some histological subtypes of lung cancer, but 
not for adenocarcinoma. We observed a substantial 
association between hsCRP concentration and the risk 
of lung cancer in the first two years of follow-up.
interpretation and implications
Unresolved chronic inflammation can generate 
reactive oxygen species and reactive nitrogen species 
that promote tumour growth through angiogenesis and 
cell proliferation.16 Given our finding of a weak and 
inconsistent association between hsCRP concentration 
and the risk of lung cancer in the longer term (>2 years 
after blood draw), systemic inflammation does not 
seem to be a likely driver of early stage lung cancer, or 
hsCRP concentration might not be capturing the risk, 
or both. In turn, the etiological role of inflammation 
in the development of lung carcinogenesis remains 
debated.17 18
As chronic inflammation could arise owing to an 
immune response to tobacco smoke exposure,19 and 
considering the lack of association we observed for 
never smokers, residual confounding by smoking 
exposure could explain some of the associations 
we observed for the period beyond two years from 
blood draw. This interpretation would also be in line 
with our observation of higher hsCRP concentration 
being associated with histological subtypes most 
strongly associated with tobacco smoking, in 
contrast with the lack of association we observed 
for adenocarcinoma. The histological types that are 
strongly driven by tobacco smoke exposure will be 
more susceptible to residual confounding by smoking 
than adenocarcinoma, for which the risk increase by 
smoking is smaller.20
In stratified analysis by time from blood draw, we 
observed a stronger positive association between 
hsCRP concentration and the risk of lung cancer in 
the first two years of follow-up, particularly for current 
smokers. This result suggests that higher hsCRP 
concentrations could be indicative of the presence of 
preclinical disease state, as opposed to being a causal 
risk factor for lung cancer. If hsCRP concentration is 
indicative of a preclinical disease state, it is natural 
to consider it as an addition to smoking-based risk 
factors for screening eligibility. Our risk discrimination 
analysis—in which we found no improvement in 
discrimination overall and a small improvement for 
diagnoses in the first two years of follow-up—suggests 
that hsCRP concentration alone is unlikely to improve 
selection of patients for lung cancer screening. 
Further, given the lack of association between hsCRP 
concentration and the risk of lung adenocarcinoma, it 
would not be appropriate to use clinical CRP tests to 
rule out the presence of lung cancer during diagnostic 
work-up of patients who are symptomatic.
strengths and weaknesses
This study has several strengths, including the use of 
prediagnostic assays of hsCRP from a large and diverse 
study population of individually matched case-control 
pairs within 20 prospective cohorts from several 
regions around the world. The large study sample 
allowed for robust risk analyses across all smoking 
status categories, and we were further able to adjust 
for circulating cotinine concentrations—an objective 
measure of recent tobacco exposure. Never and 
former smokers were oversampled allowing for well 
powered smoking-stratified risk analyses. Our 1305 
never smoker case-control pairs make this the largest 
prospective risk biomarker study for lung cancer in 
never smokers. These patients who were never smokers 
represent an increasingly important subgroup that 
previous studies were underpowered to evaluate.6 21 22
Our study was limited by the use of hsCRP 
measurements from one time point for each patient. 
Individual repeated samples would have been 
particularly useful for better evaluation of circulating 
hsCRP concentrations in the years leading up to a lung 
cancer diagnosis.
conclusions
Former and current smokers with higher hsCRP 
concentrations had a greater risk of some histological 
subtypes of lung cancer, but not adenocarcinoma. We 
observed a stronger association between higher hsCRP 
concentration and the risk of lung cancer in the first two 
years of follow-up, indicating that circulating hsCRP 
concentrations might reflect a prediagnostic disease 
state as opposed to a causal risk for lung cancer.
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